ArticleLa Radiologia medica2020
Acute and late toxicity and preliminary outcomes report of moderately hypofractionated helical tomotherapy for localized prostate cancer: a mono-institutional analysis.
Article in La Radiologia medica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Long-term outcomes of moderately hypofractionated radiotherapy (67.5 Gy in 25 fractions) for prostate cancer confined to the pelvis: a single center retrospective analysis.Radiation oncology (London, England) · 2020Trial
- Effect comparison between a new hypofractionated radiotherapy regimen and conventional moderately hypofractionated regimen for localized prostate cancer.Radiation oncology (London, England) · 2026Article
- Exploring Extravasation in Cancer Patients.Cancers · 2024Review
- Hypofractionated versus conventional fractionation external beam radiotherapy in intermediate and high risk localized prostate cancer.Discover oncology · 2024Article
- Fitness and psychological effects of tele-exercise in healthy populations. Preliminary study.Frontiers in digital health · 2024Article
- Predictors of radiation-induced late rectal toxicity in prostate cancer treatment: a volumetric and dosimetric analysis.Frontiers in oncology · 2024Article
- Risk prediction of second primary malignancies after gynecological malignant neoplasms resection with and without radiation therapy: a population-based surveillance, epidemiology, and end results (SEER) analysis.Journal of cancer research and clinical oncology · 2023Article
- Integration between Novel Imaging Technologies and Modern Radiotherapy Techniques: How the Eye Drove the Chisel.Cancers · 2022Review
- Tomotherapy-based moderate hypofractionation for localized prostate cancer: a mono-institutional analysis.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2022Article
- Risk and prognosis of secondary bladder cancer after radiation therapy for pelvic cancer.Frontiers in oncology · 2022Article
- Late Changes in the Extracellular Matrix of the Bladder after Radiation Therapy for Pelvic Tumors.Diagnostics (Basel, Switzerland) · 2021Article
- Imaging side effects and complications of chemotherapy and radiation therapy: a pictorial review from head to toe.Insights into imaging · 2021Review
- MR-Guided Hypofractionated Radiotherapy: Current Emerging Data and Promising Perspectives for Localized Prostate Cancer.Cancers · 2021Review
- Moderately Hypofractionated Helical Tomotherapy for Prostate Cancer: Ten-year Experience of a Mono-institutional Series of 415 Patients.In vivo (Athens, Greece)Article
- Moderate Hypofractionated Helical Tomotherapy for Localized Prostate Cancer in Older Patients: A Single-Institution Study of Toxicity and Outcomes.Technology in cancer research & treatmentArticle
- The effect of rectal gas on dose distribution during prostate cancer treatment using full arc and partial arc Volumetric Modulated Arc Therapy (VMAT) treatment plans.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation OncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo assess toxicity and clinical outcomes of moderately hypofractionated helical tomotherapy (HT) for the curative treatment of localized prostate cancer (PC).
methodsFrom December 2012 to May 2018, 170 patients were treated with definitive intent for PC. Thirty-four percent were low risk, 30% intermediate risk (IR) and 36% high risk (HR). All patients received 70 Gy in 28 fractions to the prostate; 61.6 Gy were delivered to the seminal vesicles for IR; pelvic lymph nodes irradiation for a total dose of 50.4 Gy was added in the HR subgroup. Toxicity was assessed using CTCAE V4.0, and biochemical failure was defined following Phoenix criteria. Time-to-event data were analyzed using the Kaplan-Meier method and log-rank test.
resultsThe median follow-up was 36 months (range 12-78); acute toxicity was as follows: G1 and G2 in 27.6% and 19.4% for GI; 53% and 24% for GU. No G ≥ 3 event was observed. For late toxicity, G ≥ 3 GI and GU rates were, respectively, 3% and 2.4% at 3 years and 3% and 4.8% at 4 years; no G4 occurred. A statistical correlation between acute or late G3 incidence and clinical or dosimetric parameters was not found. At the time of analysis, 2- and 3-year biochemical relapse-free survival rates were 90% and 87.5% and 2- and 3-year overall survival rates were 96.4% and 90%, respectively. The log-rank test revealed no difference between the risk groups in terms of biochemical control (p = 0.16).
conclusionsModerately hypofractionated RT with HT for localized prostate cancer reported excellent outcomes with mild acute and late toxicity incidence, with promising biochemical control rates.
Indexed as
Identifiers
31641931What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.